SCHEMBL6415657

SCHEMBL6415657

CC(C)(C)NC(=O)c1ccc(Cl)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
APEX1 P27695 1/20 0.61
ANO1 Q5XXA6 6/20 0.52
CYP11B2 P19099 1/20 0.49
HTT P42858 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALPL P05186 1/20 0.45
TRPA1 O75762 1/20 0.44
GPR27 Q9NS67 1/20 0.44
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
KCNMA1 Q12791 1/20 0.42
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415937 0.83 KDM4E (0.61) POLBAPEX1HTTALDH1A1LMNA
SCHEMBL6419619 0.83 POLB (0.56) POLBAPEX1HTTNPC1RAB9A
SCHEMBL4597516 0.81 FLT1 (0.55) POLBAPEX1ANO1CYP11B2NPC1
SCHEMBL12121090 0.81 POLB (0.54) POLBAPEX1ANO1
SCHEMBL14903858 0.81 GAA (0.56) CYP11B2NPC1RAB9AALDH1A1LMNA
SCHEMBL506513 0.80 DGAT1 (0.54) POLBAPEX1HTTNPC1RAB9A
SCHEMBL2335621 0.80 FLT1 (0.54) POLBAPEX1ANO1HTTNPC1
SCHEMBL13152444 0.80 ABL1 (0.58) POLBAPEX1ANO1NPC1RAB9A
SCHEMBL6420399 0.79 ALOX5AP (0.52) POLBAPEX1ANO1HTTGAA
SCHEMBL4658372 0.78 POLB (0.50) POLBAPEX1ANO1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 POLB 3216/4885APEX1 1777/4885ANO1 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.